- [Home](/) › - [FdaApprovalPulse](/v/fdaapprovalpulse) › - [Hubs](/hub/fdaapprovalpulse) › - Drug efficacy supplement (new indication or use) # FdaApprovalPulse: Drug efficacy supplement (new indication or use) **77 fdaApprovalPulse: Drug efficacy supplement (new indication or use) are listed from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration), dated 2026-05-08 to 2026-10-29; the most frequent is ELI LILLY AND CO with 11. Data last updated 2026-11-04; each record links to its official source and a full report.** Data as of 2026-11-04 · [Compiled by Zalwin](/research/fdaapprovalpulse) from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) Copy citation Download all 77 fdaApprovalPulse: Drug efficacy supplement (new indication or use) (CSV) — $4.99 → Includes: Sponsor, Product, Approval, Decided, official source URL and score · Card, Apple Pay, Google Pay or Link via Stripe [Free sample: 3 records (CSV)](/v1/verticals/fdaapprovalpulse/records.csv?type=suppl_efficacy) 77 records from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration), dated 2026-05-08 to 2026-10-29. Most frequent: ELI LILLY AND CO (11). Each record links to a full report and the official source. Last updated 2026-11-04. Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration). **Search, filter and export FdaApprovalPulse records** [Run instant live search with these filters](/v/fdaapprovalpulse?type=suppl_efficacy&channel=pseo#vt-out) [Download free 3-row sample CSV](/v1/verticals/fdaapprovalpulse/records.csv?type=suppl_efficacy) Unlock the full CSV for these filters — $4.99 → ✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days ## Get new FdaApprovalPulse records by email (free, weekly) We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email. Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe. [See this week's digest](/digest/fdaapprovalpulse) Records 77 Most frequent - ELI LILLY AND CO (11) - GENENTECH INC (5) - NOVARTIS (5) - PFIZER (4) - ABBVIE INC (3) ## How do I get new fdaApprovalPulse: Drug efficacy supplement (new indication or use) by email? Search, filter and export these records, or get alerts when new ones appear. [Search and filter](/v/fdaapprovalpulse?type=suppl_efficacy) [Watch this exact filter](/v/fdaapprovalpulse?type=suppl_efficacy#more-ways) [See alert plans](/v/fdaapprovalpulse#pricing) ## What are the top fdaApprovalPulse: Drug efficacy supplement (new indication or use) right now? | Record | Product | Approval | Decided | |---|---|---|---| | SUN PHARMA GLOBAL | ILUMYA | Drug efficacy supplement (new indication or use) | 2026-10-29 | | PFIZER | TALZENNA | Drug efficacy supplement (new indication or use) | 2026-10-26 | | PFIZER | TALZENNA | Drug efficacy supplement (new indication or use) | 2026-10-26 | | ABBVIE INC | SKYRIZI | Drug efficacy supplement (new indication or use) | 2026-10-23 | | NOVO NORDISK INC | AWIQLI FLEXTOUCH | Drug efficacy supplement (new indication or use) | 2026-10-23 | | PHARMACOSMOS | MONOFERRIC | Drug efficacy supplement (new indication or use) | 2026-10-23 | | GLAXOSMITHKLINE | JEMPERLI | Drug efficacy supplement (new indication or use) | 2026-10-19 | | GENENTECH | ENSPRYNG | Drug efficacy supplement (new indication or use) | 2026-10-15 | | NOVARTIS PHARMS CORP | COSENTYX | Drug efficacy supplement (new indication or use) | 2026-10-15 | | UCB INC | ZILBRYSQ | Drug efficacy supplement (new indication or use) | 2026-10-15 | | ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU | ANKTIVA | Drug efficacy supplement (new indication or use) | 2026-10-14 | | ELI LILLY AND CO | OLUMIANT | Drug efficacy supplement (new indication or use) | 2026-10-09 | | AMGEN INC | REPATHA | Drug efficacy supplement (new indication or use) | 2026-10-09 | | GENENTECH INC | TECENTRIQ HYBREZA | Drug efficacy supplement (new indication or use) | 2026-10-08 | | GENENTECH INC | TECENTRIQ | Drug efficacy supplement (new indication or use) | 2026-10-08 | | SEAGEN | Included in the full CSV with every column 🔒 Unlock all 77 records → | | NOVARTIS | Included in the full CSV with every column 🔒 Unlock all 77 records → | | BRISTOL | Included in the full CSV with every column 🔒 Unlock all 77 records → | Browse 35 more matching record reports - [SEAGEN](/report/fdaapprovalpulse/seagen--dfda-nda213411-s10) - [NOVARTIS](/report/fdaapprovalpulse/novartis--dfda-nda218436-s1) - [BRISTOL](/report/fdaapprovalpulse/bristol--dfda-nda214998-s13) - [GENENTECH](/report/fdaapprovalpulse/genentech--dfda-bla125486-s43) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda207924-s9) - [EISAI INC](/report/fdaapprovalpulse/eisai-inc--dfda-nda206947-s35) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda208716-s22) - [INTRABIO](/report/fdaapprovalpulse/intrabio--dfda-nda219132-s2) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda218881-s1) - [ASTRAZENECA](/report/fdaapprovalpulse/astrazeneca--dfda-nda218197-s6) - [NUVATION](/report/fdaapprovalpulse/nuvation--dfda-nda219713-s4) - [ASTRAZENECA](/report/fdaapprovalpulse/astrazeneca--dfda-nda208065-s35) - [PHARMING](/report/fdaapprovalpulse/pharming--dfda-nda217759-s6) - [BIOFRONTERA](/report/fdaapprovalpulse/biofrontera--dfda-nda208081-s40) - [BAYER HEALTHCARE](/report/fdaapprovalpulse/bayer-healthcare--dfda-nda219972-s1) - [PHARMAESSENTIA CORP](/report/fdaapprovalpulse/pharmaessentia-corp--dfda-bla761166-s13) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda215866-s44) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda215866-s45) - [GILEAD SCIENCES INC](/report/fdaapprovalpulse/gilead-sciences-inc--dfda-nda215973-s24) - [GILEAD SCIENCES INC](/report/fdaapprovalpulse/gilead-sciences-inc--dfda-nda215974-s17) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda217806-s41) - [BEIGENE](/report/fdaapprovalpulse/beigene--dfda-bla761232-s18) - [BIOCON BIOLOGICS INC](/report/fdaapprovalpulse/biocon-biologics-inc--dfda-bla761406-s2) - [NOVARTIS](/report/fdaapprovalpulse/novartis--dfda-nda215833-s37) - [ASTELLAS](/report/fdaapprovalpulse/astellas--dfda-nda203415-s26) - [ASTELLAS](/report/fdaapprovalpulse/astellas--dfda-nda213674-s16) - [SCPHARMACEUTICALS](/report/fdaapprovalpulse/scpharmaceuticals--dfda-nda209988-s7) - [MUNDIPHARMA](/report/fdaapprovalpulse/mundipharma--dfda-nda217417-s7) - [NOVARTIS](/report/fdaapprovalpulse/novartis--dfda-nda218276-s7) - [SUN PHARMA GLOBAL](/report/fdaapprovalpulse/sun-pharma-global--dfda-bla761067-s27) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda218160-s7) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda213246-s17) - [ELI LILLY AND CO](/report/fdaapprovalpulse/eli-lilly-and-co--dfda-nda208716-s21) - [EISAI INC](/report/fdaapprovalpulse/eisai-inc--dfda-bla761375-s1) - [ASTELLAS](/report/fdaapprovalpulse/astellas--dfda-bla761137-s37) More records in this hub: [page 2](/hub/fdaapprovalpulse/type/suppl-efficacy/page/2) [Browse all FdaApprovalPulse record reports](/hub/fdaapprovalpulse/records) ## Which related categories and locations should I check? ### Browse by approval type [Drug labeling or REMS supplement (1180)](/hub/fdaapprovalpulse/type/suppl-labeling) [PMA supplement (device change) (367)](/hub/fdaapprovalpulse/type/pma-supplement) [Generic drug approval (ANDA) (196)](/hub/fdaapprovalpulse/type/anda) [Drug manufacturing (CMC) supplement (55)](/hub/fdaapprovalpulse/type/suppl-manufacturing) [New drug application (NDA) (41)](/hub/fdaapprovalpulse/type/nda) [PMA original approval (new class III device) (24)](/hub/fdaapprovalpulse/type/pma-original) [Biologic license (BLA) (17)](/hub/fdaapprovalpulse/type/bla) [Other drug supplement (12)](/hub/fdaapprovalpulse/type/suppl-other) ### Browse by sponsor state (devices) [California (110)](/hub/fdaapprovalpulse/state/ca) [Minnesota (61)](/hub/fdaapprovalpulse/state/mn) [Massachusetts (37)](/hub/fdaapprovalpulse/state/ma) [Oregon (20)](/hub/fdaapprovalpulse/state/or) [Arizona (18)](/hub/fdaapprovalpulse/state/az) [Texas (18)](/hub/fdaapprovalpulse/state/tx) [Illinois (9)](/hub/fdaapprovalpulse/state/il) [Maryland (9)](/hub/fdaapprovalpulse/state/md) [Tennessee (8)](/hub/fdaapprovalpulse/state/tn) [Pennsylvania (7)](/hub/fdaapprovalpulse/state/pa) [Florida (6)](/hub/fdaapprovalpulse/state/fl) [Washington (6)](/hub/fdaapprovalpulse/state/wa) [Missouri (5)](/hub/fdaapprovalpulse/state/mo) [Wisconsin (5)](/hub/fdaapprovalpulse/state/wi) [Colorado (4)](/hub/fdaapprovalpulse/state/co) [Connecticut (4)](/hub/fdaapprovalpulse/state/ct) [Georgia (4)](/hub/fdaapprovalpulse/state/ga) [Indiana (4)](/hub/fdaapprovalpulse/state/in) [New Jersey (4)](/hub/fdaapprovalpulse/state/nj) [New York (4)](/hub/fdaapprovalpulse/state/ny) [North Carolina (3)](/hub/fdaapprovalpulse/state/nc) [Ohio (3)](/hub/fdaapprovalpulse/state/oh) ## Frequently asked questions ### How many fdaApprovalPulse: Drug efficacy supplement (new indication or use) are listed? 77 records from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration), last refreshed automatically. The most recent is dated 2026-10-29. ### Can I get alerts for Drug efficacy supplement (new indication or use)? Yes. FdaApprovalPulse can email you new records matching this filter; plans are listed on the FdaApprovalPulse page. Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration). Informational only. [RSS feed of new records](/feed/fdaapprovalpulse.xml) ## Often used together - [FDAPulse](/v/fdapulse) - [FdaNdcDirectoryPulse](/v/fdandcdirectorypulse) - [NycPropertyExemptionDetailPulse](/v/nycpropertyexemptiondetailpulse) - [MigrationRedirectAudit](/migrationredirectaudit) - [SchemaMarkupGeneratorKit](/schemageneratorkit) - [ShopifyStorefrontXray](/shopifystorefrontxray)